DK2004164T3 - Farmaceutisk sammensætning til behandling eller forebyggelse af inflammatoriske sygdomme - Google Patents

Farmaceutisk sammensætning til behandling eller forebyggelse af inflammatoriske sygdomme Download PDF

Info

Publication number
DK2004164T3
DK2004164T3 DK07745964.2T DK07745964T DK2004164T3 DK 2004164 T3 DK2004164 T3 DK 2004164T3 DK 07745964 T DK07745964 T DK 07745964T DK 2004164 T3 DK2004164 T3 DK 2004164T3
Authority
DK
Denmark
Prior art keywords
hydroxy
benzoic acid
compound
phenyl
ethylamino
Prior art date
Application number
DK07745964.2T
Other languages
English (en)
Inventor
Byoung-Joo Gwag
Sung-Ig Cho
Jae-Young Cho
Young-Ae Lee
Han-Yeol Byun
Doo-Soon Lim
Young-Bae Kwon
Jin-Hwan Lee
Bok-Seon Yoon
Chun-San An
Keun-Sil Ryu
Ki-Baik C/O Lab Of Transitional Medicine Hahm
Original Assignee
Neurotech Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38609701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2004164(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurotech Pharmaceuticals Co Ltd filed Critical Neurotech Pharmaceuticals Co Ltd
Application granted granted Critical
Publication of DK2004164T3 publication Critical patent/DK2004164T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (3)

1. Farmaceutisk sammensætning omfattende 2-hydroxybenzoesyrederivat eller dets farmaceutisk acceptable salt, hvor 2-hydroxybenzoesyrederivatet er en hvilken som helst valgt fra gruppen bestående af 2-hydroxy-5-phenethylamino-benzoesyre, 2-hydroxy-5-[2-(4-trifluormethyl-phenyl)-ethylamino]-benzoesyre, 2-hydroxy-5-[2-(2-nitro-phenyl)-ethylamino]-benzoesyre, 5-[2-(3,4-difluor-phenyl)-ethylamino]-2-hydroxy-benzoesyre, 5-[2-(3,4-dichlorphenyl)-ethylamino]-2-hydroxy-benzoesyre, 5-[2-(4-fluor-2-trifluormethyl-phenyl)-ethylamino]-2-hydroxy-benzoesyre, 5-[2-(2-fluor-4-trifluormethyl-phenyl)-ethylamino]-2-hydroxy-benzoesyre, 2-hydroxy-5-[2-(4-methoxy-phenyl)-ethylamino]-benzoesyre, 2-hydroxy-5-(2-o-tolyl-ethylamino)-benzoesyre, 2-hydroxy-5-(3-phenyl-propylamino)-benzoesyre, 5-[3-(4-fluor-phenyl)-propylamino]-2-hydroxy-benzoesyre, 5-[3-(3,4-dichlor-phenyl)-propylamino]-2-hydroxy-benzoesyre, 2-hydroxy-5-(3-p-tolyl-propylamino)-benzoesyre, og 2-acetoxy-5-[2-(4-trifluormethylphenyl)-ethylamino]-benzoesyre, til anvendelse til behandling eller forebyggelse af inflammatorisk sygdom, hvor den inflammatoriske sygdom er en hvilken som helst valgt fra gruppen bestående af gastritis, colitis, pancreatitis, arthritis, diabetisk inflammation og smerte, arteriosklerose, nefritis, hepatitis, inflammatorisk tarmsygdom, mavesår og hyperalgesi associeret med arthritis eller rheumarthritis.
2. Anvendelse af et 2-hydroxybenzoesyrederivat eller dets farmaceutisk acceptable salt, hvor 2-hydroxybenzoesyrederivatet er en hvilken som helst valgt fra gruppen bestående af 2-hydroxy-5-phenethylamino-benzoesyre, 2-hydroxy-5-[2-(4-trifluormethyl-phenyl)-ethylamino]-benzoesyre, 2-hydroxy-5-[2-(2-nitro-phenyl)-ethylamino]-benzoesyre, 5-[2-(3,4-difluor-phenyl)-ethylamino]-2-hydroxy-benzoesyre, 5-[2-(3,4-dichlor-phenyl)-ethylamino]-2-hydroxy-benzoesyre, 5-[2-(4-fluor-2-trifluormethyl-phenyl)-ethylamino]-2-hydroxy-benzoesyre, 5-[2-(2-fluor-4-trifluormethyl-phenyl)-ethylamino]-2-hydroxy-benzoesyre, 2-hydroxy-5-[2-(4-methoxy-phenyl)-ethylamino]-benzoesyre, 2-hydroxy-5-(2-o-tolyl-ethylamino)-benzoesyre, 2-hydroxy-5-(3-phenyl-propylamino)-benzoesyre, 5-[3-(4-fluor-phenyl)-propylamino]-2-hydroxy-benzoesyre, 5-[3-(3,4-dichlor-phenyl)-propylamino]-2-hydroxy-benzoesyre, 2- hydroxy-5-(3-p-tolyl-propylamino)-benzoesyre, og 2-acetoxy-5-[2-(4-trifluormethyl-phenyl)-ethylamino]-benzoesyre, i fremstillingen af et lægemiddel til behandling eller forebyggelse af inflammatorisk sygdom, hvor den inflammatoriske sygdom er en hvilken som helst valgt fra gruppen bestående af gastritis, colitis, pancreatitis, arthritis, diabetisk inflammation og smerte, arteriosklerose, nefritis, hepatitis, inflammatorisk tarmsygdom, mavesår og hyperalgesi associeret med arthritis eller rheumarthritis.
3. 2-Acetoxy-5-[2-(4-trifluormethyl-phenyl)-ethylamino]-benzoesyre og dets farmaceutisk acceptable salte.
DK07745964.2T 2006-04-13 2007-04-13 Farmaceutisk sammensætning til behandling eller forebyggelse af inflammatoriske sygdomme DK2004164T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20060033596 2006-04-13
PCT/KR2007/001801 WO2007119973A1 (en) 2006-04-13 2007-04-13 Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases

Publications (1)

Publication Number Publication Date
DK2004164T3 true DK2004164T3 (da) 2018-10-29

Family

ID=38609701

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07745964.2T DK2004164T3 (da) 2006-04-13 2007-04-13 Farmaceutisk sammensætning til behandling eller forebyggelse af inflammatoriske sygdomme

Country Status (10)

Country Link
US (4) US8455470B2 (da)
EP (1) EP2004164B1 (da)
JP (3) JP5450053B2 (da)
KR (2) KR101333753B1 (da)
CN (3) CN101538218B (da)
AU (2) AU2007239191B2 (da)
CA (1) CA2649286C (da)
DK (1) DK2004164T3 (da)
ES (1) ES2690205T3 (da)
WO (1) WO2007119973A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101204108B1 (ko) * 2009-02-09 2012-11-22 주식회사 지엔티파마 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
KR101430247B1 (ko) * 2012-01-18 2014-08-18 경희대학교 산학협력단 실내 가시광 통신을 이용한 3차원 위치 측정 방법 및 그 시스템과, 위치 기반 서비스 제공 방법
CN103819354B (zh) * 2014-02-20 2015-08-19 南京医科大学 一类n-苄基取代的氨基水杨酸2-氨基乙醇酯衍生物及其药物用途
WO2021006637A1 (ko) * 2019-07-08 2021-01-14 주식회사 지엔티파마 5-벤질아미노살리실산 유도체를 포함하는 화장품 조성물 및 이의 국소 사용방법
EP3998058A4 (en) * 2019-07-08 2023-10-04 GNT Pharma Co., Ltd COSMETIC COMPOSITION CONTAINING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND METHOD FOR TOPICAL ADMINISTRATION
CN112479912A (zh) * 2020-12-08 2021-03-12 浙江普洛家园药业有限公司 2-羟基-5-[2-(4-(三氟甲基苯基)乙基氨基)]苯甲酸晶型及其制备方法
CN113735726A (zh) * 2021-08-09 2021-12-03 浙江理工大学 一种2-羟基-5-[2-(4-(三氟甲基苯基)乙基氨基)]苯甲酸钠及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632760A (en) 1969-06-25 1972-01-04 Merck & Co Inc Treatment of inflammation
NL7008623A (da) 1969-06-25 1970-12-29
US3674844A (en) 1970-04-20 1972-07-04 Merck & Co Inc Salicylic acid derivatives
JPS6056130B2 (ja) 1978-03-20 1985-12-09 久光製薬株式会社 新規なサリチル酸誘導体
DK117484A (da) 1983-03-14 1984-09-15 Carpibem 1-(2-carbethoxy-4-benzalkylamido-phenoxy)-3-amino-2-propanoler og fremgangsmaade til fremstilling deraf samt forbindelsernes anvendelse som laegemidler
JPS60237041A (ja) 1984-03-02 1985-11-25 Yamamoto Kagaku Kogyo Kk ３−プロピオニルサリチル酸誘導体の製造法
IT1196348B (it) 1984-11-29 1988-11-16 Italfarmaco Spa Composti ad attivita'antiinfiammatoria
JP2722279B2 (ja) 1992-12-10 1998-03-04 ファイザー・インク． アミノメチレンで置換した非芳香族複素環式化合物及びサブスタンスｐのアンタゴニストとしての使用
CN1044364C (zh) * 1993-06-26 1999-07-28 河南师范大学 一种治疗肠炎和溃疡性结肠炎的药物及其制备工艺
CA2240281C (en) * 1995-12-21 2007-02-27 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases
US6451766B1 (en) * 1996-07-22 2002-09-17 Sankyo Company, Limited Neuraminic acid derivatives, their preparation and their medical use
US7205280B2 (en) * 1998-03-11 2007-04-17 Cognosci, Inc. Methods of suppressing microglial activation
US6297380B1 (en) * 1998-11-23 2001-10-02 Pfizer Inc. Process and intermediates for growth hormone secretagogues
JP2003509349A (ja) * 1999-09-15 2003-03-11 エラン ファーマシューティカルズ，インコーポレイテッド ヘテロアリールメタンスルホンアミドを使用するニューロパシー性疼痛を処置するための方法。
DK1274675T3 (da) * 2000-04-19 2004-12-06 Neurotech Co Ltd Forbindelser, sammensætninger og fremgangsmåder til forebyggelse af neurodegeneration ved akutte og kroniske skader i centralnervesystemet
US6573402B1 (en) 2000-04-20 2003-06-03 Neurotech Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
AU2002229056A1 (en) * 2000-12-07 2002-06-18 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with NMDA receptor antagonists
KR20040016849A (ko) * 2001-04-02 2004-02-25 파노라마 리서치, 인크. 치료제로 사용되는 항산화제 니트로옥사이드 및 니트론류
DK1551793T3 (da) 2002-06-19 2016-04-25 Gnt Pharma Co Ltd Tetrafluorbenzylderivater og farmaceutisk sammensætning indeholdende disse til forebyggelse og behandling af akutte og kroniske neurodegenerative sygdomme i centralnervesystemet
US20070049565A1 (en) 2005-08-24 2007-03-01 Neurotech Pharmaceuticals Co., Ltd. Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction
US20070298129A1 (en) 2005-08-24 2007-12-27 Neurotech Pharmaceuticals Co., Ltd. Compounds and compositions for treating neuronal death or neurological dysfunction

Also Published As

Publication number Publication date
US20130316988A1 (en) 2013-11-28
CN101426484B (zh) 2013-05-22
US8598383B2 (en) 2013-12-03
US20090240079A1 (en) 2009-09-24
JP5073708B2 (ja) 2012-11-14
AU2009201601A1 (en) 2009-05-14
AU2007239191B2 (en) 2010-10-28
KR101333753B1 (ko) 2013-11-28
CN103211824B (zh) 2017-04-19
JP5464720B2 (ja) 2014-04-09
WO2007119973A1 (en) 2007-10-25
EP2004164B1 (en) 2018-08-08
JP5450053B2 (ja) 2014-03-26
AU2007239191A1 (en) 2007-10-25
CN101538218A (zh) 2009-09-23
AU2009201601B2 (en) 2011-12-08
CN101426484A (zh) 2009-05-06
KR101335029B1 (ko) 2013-11-28
JP2009221210A (ja) 2009-10-01
EP2004164A4 (en) 2010-01-13
CN103211824A (zh) 2013-07-24
JP2009533422A (ja) 2009-09-17
EP2004164A1 (en) 2008-12-24
CA2649286C (en) 2013-03-12
KR20110069183A (ko) 2011-06-22
CA2649286A1 (en) 2007-10-25
JP2012153704A (ja) 2012-08-16
US20090281181A1 (en) 2009-11-12
US20120209025A1 (en) 2012-08-16
KR20090051273A (ko) 2009-05-21
CN101538218B (zh) 2013-05-29
US8455470B2 (en) 2013-06-04
ES2690205T3 (es) 2018-11-19

Similar Documents

Publication Publication Date Title
DK2004164T3 (da) Farmaceutisk sammensætning til behandling eller forebyggelse af inflammatoriske sygdomme
US10874644B2 (en) Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of synapse function
JP6395838B2 (ja) 神経疾患の処置のためのトラセミド及びバクロフェンを含む組成物
EP2560631B1 (en) Baclofen and acamprosate based therapy of neurogical disorders
IL228176A (en) Preparations for the treatment of neurological disorders
WO2009112609A1 (es) Nuevos usos del 4-fenilbutirato de sodio (4 pba) y sus sales farmacéuticamente aceptables
KR101189751B1 (ko) 세포 손상 및 염증 질환의 치료 또는 예방용 약학 조성물
BR112021013582A2 (pt) Medicamento profilático ou terapêutico para doenças neurodegenerativas
IL256992A (en) Treatment of neurological disorders based on baclofen and acamprosate
NZ614267B2 (en) New compositions for treating neurological disorders